Sanne C. F. A. Huijberts

Sanne C. F. A. Huijberts

Auto-generated profile, based on publicly available information

Sanne C. F. A. Huijberts

Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
RGRobin M. J. M. van Geel
Robin M. J. M. van Geel
EBEmilie M. J. van Brummelen
Emilie M. J. van Brummelen
FEFerry A. L. M. Eskens
Ferry A. L. M. Eskens
SHSanne C. F. A. Huijberts
Sanne C. F. A. Huijberts
FVFilip Y. F. L. de Vos
Filip Y. F. L. de Vos
JSJan H. M. Schellens
Jan H. M. Schellens
Background: Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS-mutant tumours existing treatment options, e.g. MEK inhibition, have limited efficacy due to resistance through feedback activation of epidermal growth factor receptors (HER). Methods: In this Phase 1 study, the pan-HER inhibitor dacomitinib was combined with the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutant colorectal, pancreatic and non-small-cell lung cancer (NSCLC). Patients received escalating oral doses of once daily dacomitinib and twice daily PD-0325901 to determine the recommended Phase 2 dose (RP2D). (Clinicaltrials.gov: NCT02039336). Results: Eight out of 41 evaluable patients (27 colorectal cancer, 11 NSCLC and 3 pancreatic cancer) among 8 dose levels experienced dose-limiting toxicities. The RP2D with continuous dacomitinib dosing was 15 mg of dacomitinib plus 6 mg of PD-0325901 (21 days on/7 days off), but major toxicity, including rash (85%), diarrhoea (88%) and nausea (63%), precluded long-term treatment. Therefore, other intermittent schedules were explored, which only slightly improved toxicity. Tumour regression was seen in eight patients with the longest treatment duration (median 102 days) in NSCLC. Conclusions: Although preliminary signs of antitumour activity in NSCLC were seen, we do not recommend further exploration of this combination in KRAS-mutant patients due to its negative safety profile.

9 April 2020 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SHSanne C. F. A. Huijberts
Sanne C. F. A. Huijberts
RGRobin M. J. M. van Geel
Robin M. J. M. van Geel
EBEmilie M. J. van Brummelen
Emilie M. J. van Brummelen
FOFrans L. Opdam
Frans L. Opdam
SMSerena Marchetti
Serena Marchetti
JSJan H. M. Schellens
Jan H. M. Schellens

18 November 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SHSanne C. F. A. Huijberts
Sanne C. F. A. Huijberts
MBMirjam C. Boelens
Mirjam C. Boelens
RBRene Bernards
Rene Bernards
FOFrans L. Opdam
Frans L. Opdam
Background: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAFV600E mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response and/or acquired resistance in these patients receiving therapies consisting of a backbone of BRAF and EGFR inhibition. Methods: This was a cohort study on genetic alterations in patients with BRAFV600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway. We examined tumour tissue for genetic alterations at baseline, during treatment and at progression. Results: In total, 37 patients were included in this cohort. Genetic alterations in EGFR and in PIK3CA are associated with non-response. A greater fraction of non-responders (75%) versus responders (46%) had at least one genetic alteration in other genes than TP53, APC or BRAF. Secondary resistance mutations (n = 16 patients) were observed most frequently in the PI3K pathway (n = 6) and in receptor tyrosine kinases (n = 4), leading to increased upstream signalling. Conclusions: Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance. By understanding these alterations, simultaneous or alternating treatments with targeted inhibitors might improve response duration.

9 December 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
EBEmilie M.J. Brummelen
Emilie M.J. Brummelen
SHSanne Huijberts
Sanne Huijberts
CHCarla Herpen
Carla Herpen
IDIngrid Desar
Ingrid Desar
FOFrans Opdam
Frans Opdam
JSJan Schellens
Jan Schellens
Lessons Learned Afatinib and selumetinib can be combined in continuous and intermittent dosing schedules, albeit at lower doses than approved for monotherapy. Maximum tolerated dose for continuous and intermittent schedules is afatinib 20 mg QD and selumetinib 25 mg BID. Since the anticancer activity was limited, we do not recommend to further develop this combination until better biomarkers for response and resistance are defined. Background Anti‐tumor effects of MEK inhibitors are limited in KRAS‐mutated tumors due to feedback activation of upstream epidermal growth factor receptors which reactivates the MAPK and the phosphoinositide 3‐kinase (PI3K)‐AKT pathway. Therefore, this phase I trial was initiated with the pan‐HER inhibitor afatinib plus the MEK inhibitor selumetinib in patients with KRASmt, PIK3CA wild type tumors. Methods Afatinib and selumetinib were administered according to a 3+3 design in continuous and intermittent schedules. The primary objective was safety, and the secondary objective was clinical efficacy. Results Twenty‐six patients were enrolled with colorectal cancer (n = 19), non‐small cell lung cancer (NSCLC) (n = 6), and pancreatic cancer (n = 1). Dose‐limiting toxicities occurred in six patients, including grade 3 diarrhea, dehydration, decreased appetite, nausea, vomiting, and mucositis. The RP2D was 20 mg afatinib QD and 25 mg selumetinib BID (21 days on/7 days off) for continuous afatinib dosing and for intermittent dosing with both drugs 5 days on/2 days off. Efficacy was limited with disease stabilization for 221 days in a patient with NSCLC as best response. Conclusion Afatinib and selumetinib can be combined in continuous and intermittent schedules in patients with KRASmt tumors. Although target engagement was observed, the clinical efficacy was limited.

3 March 2020 in Future Oncology
Verified
Journal Article
Closed access
SHSanne Huijberts
Sanne Huijberts
LWLiqin Wang
Liqin Wang
RORodrigo Leite de Oliveira
Rodrigo Leite de Oliveira
HRHilde Rosing
Hilde Rosing
BNBastiaan Nuijen
Bastiaan Nuijen
SWSofie Wilgenhof
Sofie Wilgenhof
The clinical benefit of treatment with BRAF- and MEK-inhibitors in melanoma is limited due to resistance associated with emerging secondary mutations. Preclinical and clinical studies have shown th...

6 February 2020 in Future Oncology
Verified
Journal Article
Closed access
SHSanne Cfa Huijberts
Sanne Cfa Huijberts
RGRobin Mjm van Geel
Robin Mjm van Geel
RBRene Bernards
Rene Bernards
JBJos H Beijnen
Jos H Beijnen
NSNeeltje Steeghs
Neeltje Steeghs
Approximately 10–15% of colorectal cancers (CRCs) harbor an activating BRAF mutation, leading to tumor growth promotion by activation of the mitogen-activated protein kinases pathway. BRAFV600E mut...